Mutations in PI3K/AKT pathway genes and amplifications of PIK3CA are associated with patterns of recurrence in gastric cancers

Oncotarget

Volumn 7, Issue 5, 2016, Pages 6201-6220

  Fang, Wen Liang ^a,b   Huang, Kuo Hung ^a,b   Lan, Yuan Tzu ^a,b   Lin, Chien Hsing ^b   Chang, Shih Ching ^a,b   Chen, Ming Huang ^a,b   Chao, Yee ^a,b   Lin, Wen Chang ^b,c   Lo, Su Shun ^b   Li, Anna Fen Yau ^a,b   Wu, Chew Wun ^a,b   Chiou, Shih Hwa ^a,b   Shyr, Yi Ming ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

Diffuse type; PI3K AKT pathway; PIK3CA amplifications; Prognosis; Recurrence pattern

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B BETA; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; PROTEIN KINASE B;

ADULT; AGED; AKT1 GENE; AKT2 GENE; AKT3 GENE; ARTICLE; CANCER RECURRENCE; CHINESE; DISEASE FREE SURVIVAL; EPSTEIN BARR VIRUS INFECTION; FEMALE; GENE; GENE AMPLIFICATION; GENE MUTATION; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METASTASIS; OVERALL SURVIVAL; PERITONEUM METASTASIS; PHOSPHATIDYLINOSITOL 3 KINASE AKT PATHWAY; PIK3CA GENE; PTEN GENE; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SOMATIC MUTATION; STOMACH ADENOCARCINOMA; STOMACH CANCER; TUMOR DIFFERENTIATION; ENZYMOLOGY; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY; PROGNOSIS; STOMACH TUMOR; TUMOR RECURRENCE;

AGED; FEMALE; GENE AMPLIFICATION; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS;

EID: 84958092479     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6641     Document Type: Article

References (39)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Wu CW, Lo SS, Shen KH, Hsieh MC, Chen JH, Chiang JH, Lin HJ, et al. Incidence and factors associated with recurrence patterns after intended curative surgery for gastric cancer. World J Surg 2003;27:153-158.
3. Deng N, Goh LK, Wang H, Das K, Tao J, Tan IB, Zhang S, et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 2012;61:673-684.
4. Wadhwa R, Song S, Lee JS, Yao Y, Wei Q, Ajani JA. Gastric cancer-molecular and clinical dimensions. Nat Rev Clin. Oncol 2013;10:643-655.
5. Willems L, Tamburini J, Chapuis N, Lacombe C, Mayeux P, Bouscary D. PI3K and mTOR signaling pathways in cancer: New data on targeted therapies. Curr. Oncol. Rep 2012;14:129-138.
6. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, González-Barón M. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 2004;30:193-204.
7. Zhou J, Chen GB, Tang YC, Sinha RA, Wu Y, Yap CS, Wang G, et al. Genetic and bioinformatic analyses of the expression and function of PI3K regulatory subunit PIK3R3 in an Asian patient gastric cancer library. BMC Med Genomics 2012;5:34.
8. Tapia O, Riquelme I, Leal P, Sandoval A, Aedo S, Weber H, Letelier P, et al. The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance. Virchows Arch. 2014;465:25-33
9. Ying J, Xu Q, Liu B, Zhang G, Chen L, Pan H. The expression of the PI3K/AKT/mTOR pathway in gastric cancer and its role in gastric cancer prognosis. Onco Targets Ther. 2015;8:2427-33.
10. Riquelme I, Saavedra K, Espinoza JA, Weber H, García P, Nervi B, Garrido M, et al. Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy. Oncotarget. 2015;6:24750-24779. doi: 10.18632/oncotarget.4990.
11. Shi J, Yao D, Liu W, Wang N, Lv H, Zhang G, Ji M, et al. Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer. BMC Cancer. 2012;12:50.
12. Siegfried Z, Bonomi S, Ghigna C, Karni R. Regulation of the Ras-MAPK and PI3K-mTOR signaling pathways by alternative splicing in cancer. Int J Cell Biol. 2013; 2013:568931.
13. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554.
14. Velho S, Oliveira C, Ferreira A, Ferreira AC, Suriano G, Schwartz S Jr, Duval A, et al. The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer 2005;41:1649-1654.
15. Barbi S, Cataldo I, de Manzoni G, Bersani S, Lamba S, Mattuzzi S, Bardelli A, et al. The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type. J Exp Clin Cancer Res 2010;29:32.
16. Sukawa Y, Yamamoto H, Nosho, K, Ito M, Igarashi H, Naito T, Mitsuhashi K, et al. HER2 expression and PI3K-Akt pathway alterations in gastric cancer. Digestion 2014;89:12-17.
17. Corso G, Velho S, Paredes J, Pedrazzani C, Martins D, Milanezi F, Pascale V, et al. Oncogenic mutations in gastric cancer with microsatellite instability. Eur J Cancer 2011;47:443-451.
18. Takahashi N, Yamada Y, Taniguchi H, Fukahori M, Sasaki Y, Shoji H, Honma Y, et al. Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer. BMC Res Notes 2014;29;7:271.
19. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202-9.
20. Lee J, van Hummelen P, Go C, Palescandolo E, Jang J, Park HY, Kang SY, et al. High-throughput mutation profiling identifies frequent somatic mutations in advanced gastric adenocarcinoma. PLoS One. 2012;7:e38892.
21. Yang Q, Shao Y, Shi J, Qu Y, Wu K, Dang S, Shi B, et al. Concomitant PIK3CA amplification and RASSF1A or PAX6 hypermethylation predict worse survival in gastric cancer. Clin Biochem. 2014;47:111-6.
22. Lee H, Hwang IS, Choi IJ, Kang YN, Park KU, Lee JH. Are PIK3CA Mutation and Amplification Associated with Clinicopathological Characteristics of Gastric Cancer? Asian Pac J Cancer Prev. 2015;16:4493-6.
23. Tran TN, Brettingham-Moore K, Duong CP, Mitchell C, Clemons NJ, Phillips WA. Molecular changes in the phosphatidylinositide 3-kinase (PI3K) pathway are common in gastric cancer. J Surg Oncol. 2013;108:113-20.
24. Yamamoto H, Watanabe Y, Maehata T, Morita R, Yoshida Y, Oikawa R, Ishigooka S, et al. An updated review of gastric cancer in the next-generation sequencing era: Insights from bench to bedside and vice versa. World J Gastroenterol 2014;20:3927-3937.
25. Yuge R, Kitadai Y, Shinagawa K, Onoyama M, Tanaka S, Yasui W, Chayama K. mTOR and PDGF Pathway Blockade Inhibits Liver Metastasis of Colorectal Cancer by Modulating the Tumor Microenvironment. Am J Pathol 2015;185:399-408.
26. Djukom C, Porro LJ, Mrazek A, Townsend CM Jr, Hellmich MR, Chao C. Dual inhibition of PI3K and mTOR signaling pathways decreases human pancreatic neuroendocrine tumor metastatic progression. Pancreas 2014;43:88-92.
27. Fang Y, Xue JL, Shen Q, Chen J, Tian L. MicroRNA-7 inhibits tumor growth and metastasis by targeting the phosphoinositide 3-kinase/Akt pathway in hepatocellular carcinoma. Hepatology 2012;55:1852-1862.
28. Wen YG, Wang Q, Zhou CZ, Qiu GQ, Peng ZH, Tang HM. Mutation analysis of tumor suppressor gene PTEN in patients with gastric carcinomas and its impact on PI3K/AKT pathway. Oncol Rep 2010;24:89-95.
29. Kalinsky K, Jacks LM, Heguy A, Patil S, Drobnjak M, Bhanot UK, Hedvat CV, et al. PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res 2009, 15:5049-5059.
30. Mao C, Yang ZY, Hu XF, Chen Q, Tang JL. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and metaanalysis. Ann Oncol 2012, 23:1518-1525.
31. Catasus L, Gallardo A, Cuatrecasas M, Prat J. PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters. Mod Pathol 2008, 21:131-139.
32. Janku F, Garrido-Laguna I, Petruzelka LB, Stewart DJ, Kurzrock R. Novel therapeutic targets in non-small cell lung cancer. J Thorac Oncol 2011, 6:1601-1612.
33. Nakayama M, Hisatsune J, Yamasaki E, Isomoto H, Kurazono H, Hatakeyama M, Azuma T, et al. Helicobacter pylori VacA-induced inhibition of GSK3 through the PI3K/Akt signaling pathway. J Biol Chem. 2009;284:1612-1619.
34. Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS, Cristiano BE, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 2004;64:7678-81.
35. Yamamoto H, Shigematsu H, Nomura M, Lockwood WW, Sato M, Okumura N, Soh J, et al. PIK3CA mutations and copy number gains in human lung cancers. Cancer Res. 2008;68:6913-21.
36. Sobin L, Gospodarowicz M, Wittekind C, eds. TNM Classification of Malignant Tumours In: 7th ed. International Union Against Cancer (UICC). New York: Wiley, 2009.
37. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, et al. ACTS-GC Group. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1810-1820.
38. Soh J, Okumura N, Lockwood WW, Yamamoto H, Shigematsu H, Zhang W, Chari R, et al. Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. PLoS One 2009;4:e7464.
39. Lin CH, Huang MC, Li LH, Wu JY, Chen YT, Fann CS. Genome-wide copy number analysis using copy number inferring tool (CNIT) and DNA pooling. Hum Mutat. 2008;29:1055-62.